Last Price
10.21
Today's Change
-1.43 (12.28%)
Day's Change
10.21 - 11.19
Trading Volume
16,052
Market Cap
0
Shares Outstanding
0
Avg Volume
0
Avg Price (50 Days)
0.00
Avg Price (200 Days)
0.00
PE Ratio
0.00
EPS
0.00
Earnings Announcement
Previous Close
0.00
Open
0.00
Day's Range
0.0 - 0.0
Year Range
0.0 - 0.0
Trading Volume
0
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.